COMPANY RESEARCHAn original Phase 1 DKY709 abstract at AACR 2026 describes an oral IKZF2 molecular glue and reports human pharmacodynamic, PK, and preliminary efficacy data through 2024-09-05.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
NEORAL cyclosporine is a classic benchmark for oral cyclic peptides and microemulsion preconcentrates; it should not be assumed bioequivalent to Sandimmune.
An original Phase 1 DKY709 abstract at AACR 2026 describes an oral IKZF2 molecular glue and reports human pharmacodynamic, PK, and preliminary efficacy data through 2024-09-05.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| cyclosporine / NEORAL | Cyclophilin / Calcineurin · Immunosuppression-related indications | Approved | Label reports systemic exposure and formulation differences |
| DKY709 | IKZF2 / Helios · See individual trial / indication; not individually confirmed in this review | Phase 1 | Human target degradation and preliminary safety / efficacy |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Monte Rosa announced that Novartis initiated a second Phase 2 study of the VAV1 molecular glue degrader MRT-6160, also called DDY391, in active moderate to severe psoriatic arthritis. The randomized, double-blind, placebo-controlled trial will assess efficacy, safety, tolerability, and dose response. The first patient visit triggers a $37.5 million milestone payment.
Unnatural Products licensed an undisclosed cardiovascular program to Novartis. Terms include up to $100 million in upfront and pre-IND payments, plus up to $1.7 billion in later milestones and royalties. The platform supports oral and injectable macrocycles; the announcement does not establish the specific program’s route or imply all contingent payments have been received.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.